Craig Fenwick
Overview
Explore the profile of Craig Fenwick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1385
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Subunit protein CD40.SARS.CoV2 vaccine induces SARS-CoV-2-specific stem cell-like memory CD8 T cells
Nguema L, Picard F, El Hajj M, Dupaty L, Fenwick C, Cardinaud S, et al.
EBioMedicine
. 2024 Dec;
111():105479.
PMID: 39667270
Background: Ideally, vaccination should induce protective long-lived humoral and cellular immunity. Current licensed COVID-19 mRNA vaccines focused on the spike (S) region induce neutralizing antibodies that rapidly wane. Methods: Herein,...
2.
Schwab J, Foglierini M, Pescosolido E, Pacheco I, Ruiz Buendia G, Madelon N, et al.
Commun Med (Lond)
. 2024 Nov;
4(1):254.
PMID: 39616213
Background: New onsets of chronic urticaria (CU) have been reported after repeated immunizations, mainly with the Moderna mRNA-1273 vaccine (Spikevax). This study aims to evaluate patients with CU after COVID-19...
3.
Gillard J, Suffiotti M, Brazda P, Venkatasubramanian P, Versteegen P, de Jonge M, et al.
Nat Commun
. 2024 Mar;
15(1):2133.
PMID: 38459022
Many countries continue to experience pertussis epidemics despite widespread vaccination. Waning protection after booster vaccination has highlighted the need for a better understanding of the immunological factors that promote durable...
4.
Moullan N, Asiago J, Stecco K, Hadi S, Albizem M, Tieu H, et al.
Infect Dis Ther
. 2024 Jan;
13(1):173-187.
PMID: 38221576
Introduction: COVID-19 remains a significant risk for the immunocompromised given their lower responsiveness to vaccination or infection. Therefore, passive immunity through long-acting monoclonal antibodies (mAbs) offers a needed approach for...
5.
Raineri A, Radtke T, Rueegg S, Haile S, Menges D, Ballouz T, et al.
Nat Commun
. 2023 Nov;
14(1):7764.
PMID: 38012137
Understanding the development of humoral immune responses of children and adolescents to SARS-CoV-2 is essential for designing effective public health measures. Here we examine the changes of humoral immune response...
6.
Fenwick C, Turelli P, Duhoo Y, Lau K, Herate C, Marlin R, et al.
J Infect
. 2023 Oct;
87(6):524-537.
PMID: 37852477
Objectives: Due to the rapid evolution of SARS-CoV-2 to variants with reduced sensitivity to vaccine-induced humoral immunity and the near complete loss of protective efficacy of licensed therapeutic monoclonal antibodies,...
7.
Banga R, Procopio F, Lana E, Gladkov G, Roseto I, Parsons E, et al.
Cell Host Microbe
. 2023 Sep;
31(10):1714-1731.e9.
PMID: 37751747
Although gut and lymph node (LN) memory CD4 T cells represent major HIV and simian immunodeficiency virus (SIV) tissue reservoirs, the study of the role of dendritic cells (DCs) in...
8.
Joo V, Petrovas C, de Leval L, Noto A, Obeid M, Fenwick C, et al.
Front Immunol
. 2023 Aug;
14:1213375.
PMID: 37622123
Therapeutic monoclonal antibodies (mAb) targeting the immune checkpoint inhibitor programmed cell death protein 1 (PD-1) have achieved considerable clinical success in anti-cancer therapy through relieving T cell exhaustion. Blockade of...
9.
Godinho R, Noto A, Fenwick C, Stravodimou A, Hugelshofer S, Peters S, et al.
J Immunother Cancer
. 2023 Jun;
11(6).
PMID: 37380369
Cytokine storm induced by anti-human epidermal growth factor receptor-2 (HER2) therapies has not been reported. We report a patient with breast cancer treated with trastuzumab/pertuzumab who developed severe biventricular dysfunction...
10.
Fallet B, Foglierini M, Porret R, Alcaraz-Serna A, Sauvage C, Jenelten R, et al.
J Infect
. 2023 Jun;
87(2):111-119.
PMID: 37321353
Objectives: Intradermal skin test (IDT) with mRNA vaccines may represent a simple, reliable, and affordable tool to measure T cell response in immunocompromised patients who failed to mount serological responses...